Previous 10 | Next 10 |
Gainers: CTI BioPharma (NASDAQ:CTIC) +40%. Oak Street Health (NYSE:OSH) +23%. AVITA Medical (NASDAQ:RCEL) +15%. Axsome Therapeutics (NASDAQ:AXSM) +14%. Protagonist Therapeutics (NASDAQ:PTGX) +12%. Losers: GoodRx Holdings (NASDAQ:GDRX) -40%. Semler Scientific...
Protagonist press release (NASDAQ:PTGX): Q4 GAAP EPS of -$0.77 beats by $0.02. Revenue of $8.62M (+52.6% Y/Y) beats by $4.62M. For further details see: Protagonist GAAP EPS of -$0.77 beats by $0.02, revenue of $8.62M beats by $4.62M
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Pivotal Phase 3 VERIFY study of rusfertide in polycythemia vera expected to initiate in Q1 2022 Topline results from the Phase 2 IDEAL study of PN-943 in ulcerative coli...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips On the whole, drug stocks performed very badly in 2021, as the SPDR S&P Biotech ETF (NYSEARCA: XBI ) tumbled nearly 27%. And signaling that the sector’s woes aren’t over yet, XBI sunk about 16%...
Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference PR Newswire NEWARK, Calif. , Feb. 10, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Di...
Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it has been almost entirely resolved. The current valuation is still a deep discount fro...
Protagonist Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference Company to also participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference PR Newswire NEWARK, Calif. , Jan. 4, 2022 /PRNewswire/ -- Protagonis...
Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting A new Phase 2 study of rusfertide in PV patients with high hematocrit levels demonstrated rapid hematocrit control without the need for therapeutic phlebotomy ...
Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit PR Newswire NEWARK, Calif. , Dec. 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V....
Protagonist Therapeutics (NASDAQ:PTGX) has selected PN-235 (JNJ-77242113) as the final candidate to advance into phase 2 under collaboration with Johnson & Johnson (NYSE:JNJ) division Janssen Biotech. The oral interleukin-23 (IL-23) antagonist will be investigated in phase 2 studies for p...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...